摘要
目的观察血脂康对急性冠脉综合征患者血清一氧化氮(NO)及一氧化氮合酶(NOS)的影响。方法随机选择急性冠脉综合征病患者67例,将其随机分为血脂康治疗组35例,阿托伐他汀组32例,并对两组患者治疗前后血清NO及NOS含量水平进行对比分析。结果血脂康和阿托伐他汀均可升高急性冠脉综合征患者血清NO及NOS水平,其作用无明显差异(P>0.05)。结论血脂康可抑制脂质过氧化反应,保护血管内皮功能,对急性冠脉综合征的防治具有重要意义。
Objective To investigate the effects of Xuezhikang on serum nitric oxide（NO）and nitric oxide synthase（NOS） in acute coronary syndrome（ACS）, Methods 67 cases of ACS were divided into two groups, xuezhikang group 35 cases and atorvastatin group 32 cases. The level of serum NO and NOS before and after therapy were analyzed comparatively, Results Xuezhikang and atorvastatin could increase the level of NO and NOS in ACS, the effect was not obviously different. Conclusion Xuezhikang can restrain lipid oxidation and preserve vascular endothelial function by regulating lipid therapy, and has the important significance for prevention and cure of ACS.
出处
《中国药业》
CAS
2007年第12期30-31,共2页
China Pharmaceuticals
关键词
冠心病
一氧化氮
一氧化氮合酶
血脂康
coronary heart disease
nitric oxide
nitric oxide synthase
Xuezhikang
